The National Medical Products Administration (NMPA) granted conditional market approval for Mprosevir, the first innovative Class 1 drug in China developed with AI assistance. Created by Westlake University researchers, it uses an AI-powered approach combined with DNA-encoded library (DEL) technology to screen 49 billion compounds, narrowing candidates to nine in days. The small-molecule inhibitor targets the 3CLpro enzyme essential for SARS-CoV-2 replication. The team completed clinical trials in just 3.5 years — a stark contrast to the traditional 10–15-year timeline.
About the Author
